Gabriel Cohn Net Worth

The estimated Net Worth of Gabriel Cohn is at least $3.99 Tausend dollars as of 1 January 2022. Gabriel Cohn owns over 4,290 units of Homology Medicines Inc stock worth over $3,990 and over the last 5 years he sold FIXX stock worth over $0. In addition, he makes $0 as Chief Medical Officer at Homology Medicines Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Gabriel Cohn FIXX stock SEC Form 4 insiders trading

Gabriel has made over 1 trades of the Homology Medicines Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently he exercised 4,290 units of FIXX stock worth $3,990 on 1 January 2022.

The largest trade he's ever made was exercising 4,290 units of Homology Medicines Inc stock on 1 January 2022 worth over $3,990. On average, Gabriel trades about 1,073 units every 0 days since 2019. As of 1 January 2022 he still owns at least 4,290 units of Homology Medicines Inc stock.

You can see the complete history of Gabriel Cohn stock trades at the bottom of the page.

Gabriel Cohn biography

Dr. Gabriel M. Cohn M.D. serves as Chief Medical Officer of the Company. Prior to joining Homology, Dr. Cohn was Vice President, Clinical Development Lead at AVROBIO, Inc., a clinical-stage gene therapy company, from November 2017 to November 2019. Prior to AVROBIO, Dr. Cohn served as Vice President and Head of Global Clinical and Medical Affairs at OvaScience, Inc., a biotechnology company, from 2015 to July 2017. Prior to that, Dr. Cohn spent seven years at Shire Plc, a biotechnology company, including Shire Human Genetic Therapies (HGT), where he most recently held the position of Senior Medical Director, Clinical Sciences from 2012 to 2015, and prior to that served in roles of increasing responsibility including Interim Global Franchise Medical Lead, Gaucher Disease in 2011 and Medical Director, North America from 2008 to 2011. Prior to joining the biotechnology industry, Dr. Cohn served as the Chief, Division of Clinical and Reproductive Genetics and Medical Director, Genetic Services at Baystate Medical Center and as Assistant Professor at Tufts University School of Medicine. He began his academic career as the Director, Reproductive Genetics at SUNY Health Science Center (HSC) at Syracuse (now Upstate). Dr. Cohn has a B.S. in Biology from Brooklyn College, an M.D. from SUNY HSC at Syracuse School of Medicine and an M.B.A. from University of Massachusetts Amherst.

How old is Gabriel Cohn?

Gabriel Cohn is 61, he's been the Chief Medical Officer of Homology Medicines Inc since 2019. There are 4 older and 14 younger executives at Homology Medicines Inc. The oldest executive at Homology Medicines Inc is Steven Gillis, 67, who is the Independent Director.

What's Gabriel Cohn's mailing address?

Gabriel's mailing address filed with the SEC is C/O HOMOLOGY MEDICINES INC.,, ONE PATRIOTS PARK, BEDFORD, MA, 01730.

Insiders trading at Homology Medicines Inc

Over the last 7 years, insiders at Homology Medicines Inc have traded over $108,214,465 worth of Homology Medicines Inc stock and bought 3,033,333 units worth $51,999,993 . The most active insiders traders include Steven Gillis, James Edeerfield Management... und Kush Parmar. On average, Homology Medicines Inc executives and independent directors trade stock every 26 days with the average trade being worth of $106,785. The most recent stock trade was executed by Paul Alloway on 25 March 2024, trading 23,530 units of FIXX stock currently worth $21,883.

What does Homology Medicines Inc do?

homology medicines is a genetic medicines company translating proprietary gene editing and gene therapy technologies into novel treatments for patients with rare diseases.

Complete history of Gabriel Cohn stock trades at Homology Medicines Inc

Homology Medicines Inc executives and stock owners

Homology Medicines Inc executives and other stock owners filed with the SEC include:

• Arthur Tzianabos,
  President, Chief Executive Officer, Director
• Tim Kelly,
  Chief Technical Operations Officer
• Albert Seymour,
  Chief Scientific Officer
• W. Bradford Smith,
  Chief Financial Officer, Treasurer and Secretary
• Dr. Arthur O. Tzianabos Ph.D.,
  Pres, CEO & Director
• Dr. Albert Seymour Ph.D.,
  Chief Scientific Officer
• W. Bradford Smith CPA, M.B.A.,
  CFO & Treasurer
• Alise Reicin,
  Independent Director
• Kush Parmar,
  Independent Director
• Mary Thistle,
  Independent Director
• Richard Gregory,
  Independent Director
• Matthew Patterson,
  Independent Director
• Steven Gillis,
  Independent Director
• Jeffrey Poulton,
  Director
• Gabriel Cohn,
  Chief Medical Officer
• Cara Mayfield,
  Director of Corp. Communications
• Dr. Deborah Kinch Ph.D.,
  Chief Devel. Officer
• Dr. Julie Jordan M.D.,
  Sr. VP and Head of Clinical Devel. & Operations
• Michael Blum M.B.A.,
  Chief Commercial Officer
• Dr. Gabriel M. Cohn M.B.A., M.D.,
  Chief Medical Officer
• Melissa Gelormini,
  VP of HR
• Theresa McNeely,
  Chief Communications Officer & Patient Advocate
• Dr. Paul Alloway J.D., Ph.D.,
  Chief Legal Officer & Sec.
• Timothy P. Kelly M.B.A.,
  Chief Operating Officer
• Dr. Saswati Chatterjee Ph.D.,
  Co-Founder & Member of Scientific Advisory Board
• Ventures Iv, L.P.5 Am Co In...,
  
• Ventures Iv, L.P.5 Am Partn...,
  
• Institutes For Bio Medical ...,
  
• Ventures, Llcvv Manager Llc...,
  
• Holdings (Private) Ltd Full...,
  
• Cameron Wheeler,
  Director
• Siyamak Rasty,
  Chief Operating Officer
• James Edeerfield Management...,
  
• James Edeerfield Management...,
  
• Venture Fund Viii, L.P.Arch...,
  
• Springs Capital Management ...,
  
• Venture Fund Viii, L.P.Arch...,
  
• Charles Jr Michaud,
  See Remarks
• Paul Alloway,
  See Remarks
• Michael Lee Blum,
  Chief Commercial Officer
• Julie Jordan,
  Chief Medical Officer